Int J Stem Cells.  2014 May;7(1):12-22.

Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study

• Ismail ZM
• Amin NM
• Yacoub MF
• Mohamed AM

Abstract

BACKGROUND AND OBJECTIVES
Myelo-suppression is the most common toxicity encountered in the oncology clinic today. This study was planned to investigate the possible protective and therapeutic role of the traditional Chinese Medicinal Herb; Astragalus Membranaceus (AM), on chemotherapy-induced myelosuppression.
METHODS AND RESULTS
This study was carried out on thirty six adult male albino rats. They were divided into: Group I Control Group (n=6) received a vehicle of phosphate buffered saline (PBS) solution. Group II (n=12) were injected I.P. with cyclophosphamide (CY) for 3 days (gIIa n =6) and continued for one more week to receive AM orally (gIIb n=6). Group III (n=6) received CY I.P. together with AM orally for 3 days. Group IV (n=12) received AM orally for one week (gIVa n=6) and continued for extra three days receiving CY I.P. with AM orally (gIVb n=6). Blood samples were analysed for Total Leucocytic Count and Lymphocytic Count. Counting of CD34 +ve cells in bone marrow was performed by flowcytometry. Bone marrow sections were subjected to H&E stain as well as immunohistochemical staining for anti- CD20 antibody. The mean area % of cellular bone marrow regions occupied by developing haemopoietic cells, mean area of fat cells and mean number of CD20 immunopositive B lymphocytes in the bone marrow were measured by histomorphometric studies and statistically compared. AM proved to have a myelo-protective and myelo-therapeutic capacity, evidenced at both laboratory and morphological levels.
CONCLUSIONS
The greatest myelo-potentiating effect of AM was achieved when supplied before and together with CY therapy.

Keyword

Myelo-suppression; Cyclophosphamide; CD34; CD20; Astragalus Membranaceus

MeSH Terms

Adipocytes
Adult
Animals
Asian Continental Ancestry Group
Astragalus membranaceus*
B-Lymphocytes
Bone Marrow
Cyclophosphamide
Drug Therapy*
Humans
Male
Plants, Medicinal
Rats*
Cyclophosphamide

Figure

• 

  Fig. 1. (A) Comparing the mean values of TLC in the blood of control and experimental groups. (B) Comparing the mean values of lymphocytic countin the blood of control and experimental groups. (C) Comparing the mean values of the percentage of bone marrow CD34 immunopositive cells by flowcytometry. *p<0.05 as compared to GI, λp<0.05 as compared togIVa, αp<0.05 as compared to gIIa, □p<0.05 as compared to gIIb.

• 

  Fig. 2. (A) A photomicrograph of a transverse section (T.S) in the mid-shaft of femur from control group (GI) showing developing HSCs. Some cells are irregular in outline and show mitotic figures (black arrows), other cells arespindle-shaped (arrow heads). Different stages of myeloid cells are predominant, as well as erythroid cells (green arrows) in addition to megakaryocytes (blue arrows) and macrophages (yellow arrow). Pale nuclei in the background belong to adventitial reticular cells (purple arrows). A blood sinusoid (S) is demonstrated lined by endothelial cells (white arrow). Note interruption of the wall of the sinusoid by a cell passing through it (curved arrow) (H&E, ×1,000). (B) A photomicrograph of a transverse section (T.S) in the mid-shaft of femur fromgIIa showing BM cavities displaying large sized fat cells (F). A dilated blood sinusoid (S) is lined with hypertrophied endothelial cells (brown arrows). Several large branched cells containing engulfed black deposited material, probably macrophages, are seen (yellow arrows). Note the presence of acidophilic granular exudate material in the stromal background (thick arrow) and the presence of several damaged adventitial cells (curved arrows) (H&E, ×1,000). (C) A photomicrograph of T.S in the midshaft of femur from gIIb showing improved bone marrow cellularity, with presence of more developing HSCs. Some of HSCs are spindle-shaped (arrow heads), others have irregular outline and exhibit large nuclei (curved arrows), while others exhibit pyknotic nuclei (brown arrow). Some cells show cytoplasmic vacuolations (red arrows). Note erythroid cells and RBCs (green arrows). Megakaryocyte (blue arrow) is the largest cell seen, characterized by having lobulated nucleus and abundant cytoplasm.Acidophilic exudate material is seen in the intercellular spaces (thick arrow) (H&E, ×1,000). (D) A photomicrograph of T.S in the midshaft of a femur from GIII showing groups of developing HSCs; some of which are spindle shaped (arrow heads) and erythroid cells (green arrow), among oval shaped fat cells. Nuclei of the developing cells are large and darkly stained, while pale nuclei in the background belong to adventitial reticular cells (purple arrows). Note the presence of a multi-nucleated phagocytic cell (yellowarrow). A fat cell (F) is seen bounded by adventitial reticular and haemopoietic cells (H&E, ×1,000). (E) A photomicrograph of T.S in the midshaft of femur from gIVa showing overcrowding of the bone marrow cavity with several developing HSCs exhibiting prominent nuclei. Many cells are spindle-shaped (arrow heads), others exhibit mitotic figures (black arrows). Numerous eosinophils are observed (white arrows). Spaces occupied by fat cells are small but clearly seen between HSCs (yellow arrow). Pale nuclei in the background belong to adventitial reticular cells (purple arrows). A longitudinal section in a small blood vessel is detected engorged with RBCs (green arrow) (H&E, ×1,000). (F) A photomicrograph of T.S in the midshaft of femur from gIVb showing moderate population of bone marrow with developing HSCs, some of which are spindle-shaped (arrowheads), others showmitotic figures (black arrows). Blood sinusoids are seen lined by endothelial cells (red arrows), full with RBCs (green arrow) and WBCs, while macrophages (yellow arrows) are seen bordering blood sinusoids (H&E, ×1,000).

• 

  Fig. 3. (A) A photomicrograph of T.S in the midshaft of femur from the control group (GI) showing brown granular cytoplasmic immunoreactivity of some cells (arrows) (Anti-CD20 Immunostaining ×1,000). (B) A photomicrograph of T.S in the midshaft of femur from gIIa showing a CD20 immunoreactive cell exhibiting brown cytoplasmic granules (arrow) (Anti-CD20 Immunostaining ×1,000). (C) A photo-micrograph of T.S in the midshaft of femur from gIIbshowingCD20immunoreactive cells exhibiting diffuse brown cytoplasmic granules (arrows). Note grouping of cells between a blood vessel (BV) and a blood sinusoid (S). (Anti-CD20 Immunostaining ×1,000). (D) A photo-micrograph of T.S in the midshaft of femur from GIIIshowing diffuse, brown granular cytoplasmic immunoreactivity in many cells (black arrows) closely related to blood sinusoid. Immunoreactive cells are also seen inside the lumen of a sinusoid (S), some are crossing the sinusoidal wall (red arrows) (Anti-CD20 Immunostaining ×1,000). (E) A photomicrograph of T.S in the midshaft of femur from gIVashowing brown granular cytoplasmic immunoreactivity in many cells (arrows). Cells have rounded or oval nuclei (Anti-CD20 Immunostaining ×1,000). (F) A photomicrograph of T.S in the midshaft of femur from gIVb showing diffuse brown granular cytoplasmic immunoreactivity of some cells (black arrows). Some of the cells (redarrows) are seen crossing the blood sinusoid (S) (Anti-CD20 Immunostaining ×1,000).

• 

  Fig. 4. (A) Comparing the mean values of mean area percent of cellular bone marrow regions. (B) Comparing the mean values of area of fat cells in the control and experimental groups. (C) Comparing the mean values of bone marrow CD20 immuno-positive cells number in the control and experimental groups. *P <0.05 as compared to GI, λP < 0.05 as compared togIVa, αP <0.05 as compared to gIIa, □P<0.05 as compared to gIIb.

Reference

References

1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006. 106:2258–2266.

2. Pass GJ, Carrie D, Boylan M, Lorimore S, Wright E, Houston B, Henderson CJ, Wolf CR. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. Cancer Res. 2005. 65:4211–4217.

3. Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006. 17:1205–1212.

4. Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol. 2004. 70:261–264.

5. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005. 10:427–437.

6. Wang J, Tong X, Li P, Cao H, Su W. Immuno-enhancement effects of Shenqi Fuzheng Injection on cyclophosphamide-induced immunosuppression in Balb/c mice. J Ethnopharmacol. 2012. 139:788–795.

7. Li J, Zhong Y, Li H, Zhang N, Ma W, Cheng G, Liu F, Liu F, Xu J. Enhancement of Astragalus polysaccharide on the immune responses in pigs inoculated with foot-and-mouth disease virus vaccine. Int J Biol Macromol. 2011. 49:362–368.

8. Shao BM, Xu W, Dai H, Tu P, Li Z, Gao XM. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem Biophys Res Commun. 2004. 320:1103–1111.

9. Macedo A, Orfão A, Vidriales MB, López-Berges MC, Valverde B, González M, Caballero MD, Ramos F, Martínez M, Fernández-Calvo J, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol. 1995. 70:189–194.

10. Kiernan JA. Histological and histochemical methods: theory and practice. 3rd ed. London, New York & New Delhi: Arnold publisher;2001. 111–162.

11. Bancroft JD, Cook HC. Immunocytochemistry. Manual of histological techniques and their diagnostic application. 2nd ed. Edinburgh, New York: Churchill Livingstone;1994. 263–325.

12. Richard H. “Chapter 7: B Lymphocyte Development and Biology”. Paul W, editor. Fundamental Immunology. 6th ed. Philidelphia, PA: Lippincott Williams & Wilkins;2008. 237–269.

13. Armitage P, Berry G. Armitage P, Berry G (Geoffrey), editors. Statistical methods in medical reseach. 3rd ed. London: Blackwell Scientific Publications;1994. 12–48.

14. Haubitz M. Acute and Long-term Toxicity of Cyclophosphamide. Transplantationsmedizin. 2007. 19:26–31.

15. Zhao AB, Yu B, Wu XL, Cao KJ, Li EQ, Li QM, Chen XY. Protective effects on myelosuppression mice treated by three different classic Chinese medicine formulae. Pharmacogn Mag. 2011. 7:133–140.

16. Underwood JCE. Cellular injury in Part 1 of General and Systemic pathology. fourth edition. ElsevierInc;2007. chapter 6. 105–107.

17. Ross M, Pawlina W. Bone marrow and formation of blood cells (haemopoiesis). Histology: A Text and Atlas with Correlated Cell and Molecular Biology. 6th ed. Baltimore, Philadelphia: Wolters Kluwer, Lippincott Williams & Wilkins;2011. 289–300.

18. Liu S, Hu P, Hou Y, Li P, Li X, Tian Q. The additive effect of mesenchymal stem cells and bone morphogenetic protein 2 on γ-irradiated bone marrow in mice. Cell Biochem Biophys. 2011. 61:539–550.

19. McGuire TR, Brusnahan SK, Bilek LD, Jackson JD, Kessinger MA, Berger AM, Garvin KL, O’Kane BJ, Tuljapurkar SR, Sharp JG. Inflammation associated with obesity: relationship with blood and bone marrow endothelial cells. Obesity (Silver Spring). 2011. 19:2130–2136.

20. Young B, Lowe J, Stevens A, Heath J. Blood. Wheater’s Functional Histology A Text and Colour Atlas. 5th ed. Philadelphia, USA: Churchill Livingstone Elsevier;2007. 42–61.

21. Lv Y, Feng X, Zhu B. Study on effect of Astragalus membranaceus injection on hematopoiesis in anemic mice with myelosuppression. Zhong Yao Cai. 2005. 28:791–793.

22. Zhu X, Zhu B. Effect of Astragalus membranaceus injection on megakaryocyte hematopoiesis in anemic mice. Hua Xi Yi Ke Da Xue Xue Bao. 2001. 32:590–592.

23. Wei H, Sun R, Xiao W, Feng J, Zhen C, Xu X, Tian Z. Traditional Chinese medicine Astragalus reverses predominance of Th2 cytokines and their up-stream transcript factors in lung cancer patients. Oncol Rep. 2003. 10:1507–1512.

24. Chen Y, Zhu B, Zhang L, Yan S, Li J. Experimental study of the bone marrow protective effect of a traditional Chinese compound preparation. Phytother Res. 2009. 23:823–826.

25. Cho WC, Leung KN. In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol. 2007. 113:132–141.

26. Syrjälä M1 Ruutu T, Jansson SE. A flow cytometric assay of CD34-positive cell populations in the bone marrow. Br J Haematol. 1994. 88:679–684.

27. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, Oliver JA, Bowen K, Steeber DA, Haas KM, Poe JC, Tedder TF. Mouse CD20 expression and function. Int Immunol. 2004. 16:119–129.